IN Brief:
- Fermotein has received EU novel food authorisation for Rhizomucor pusillus mycelium.
- The approval creates a regulated route for whole-food mycelium applications in protein powders, snacks, dairy alternatives, and functional foods.
- Europe’s biomass fermentation pipeline has gained a clearer commercial pathway after years of slow regulatory progress.
The Protein Brewery has received European Union novel food authorisation for Fermotein, giving the Dutch food-tech company a formal route to sell its mycelium-based ingredient across the bloc.
The European Commission has authorised Rhizomucor pusillus mycelium for placement on the EU market under the Novel Food Regulation. Fermotein is positioned as a whole-food fungal biomass ingredient for use in protein powders, snack bars, dairy alternatives, and functional foods.
The approval is a significant regulatory step for biomass fermentation. Alternative protein development has often moved faster in the laboratory than in the market, with safety assessment, production validation, application performance, scale-up economics, and consumer acceptance all acting as constraints. Novel food authorisation gives Fermotein the legal foundation needed for broader commercial development in Europe.
The ingredient’s value will now be tested in formulation and processing. Mycelium ingredients need to perform across taste, texture, nutrition, solubility, colour, stability, and cost. They also need to work within existing production systems or justify investment in new process capability. Evaluation will extend well beyond protein content into mixing, extrusion, baking, hydration, drying, filling, and storage performance.
The approval arrives during a more disciplined phase for alternative proteins. Venture funding has cooled, several plant-based categories have lost momentum, and manufacturers are paying closer attention to unit economics. That shift is forcing the sector away from broad category excitement and toward reliable supply, validated safety, repeatable functionality, and applications that solve clear formulation problems.
Europe’s regulatory pathway remains demanding, but that difficulty can give approved ingredients a stronger credibility base once they pass. Food companies working in sensitive categories need regulatory certainty, especially where ingredients are used in high-protein, functional, or nutritionally positioned products. The authorisation should make serious development work easier because Fermotein can now be assessed as an approved ingredient rather than a speculative future option.
Fermotein also fits into wider reformulation pressure. Manufacturers are searching for proteins that can improve nutrition profiles without relying entirely on dairy, soy, pea, or wheat-based systems. In breakfast and cereal formats, reformulation work across Europe has already shown how nutrition, fibre, sugar reduction, and ingredient functionality are becoming more closely linked. Mycelium-based ingredients may offer another route for brands trying to combine protein enrichment with texture and cleaner label positioning.
Scale remains the next test. Fermentation ingredients can offer land-use efficiency and controlled production, but commercial supply depends on fermentation capacity, downstream processing, drying, quality systems, and energy cost. If production remains expensive, the ingredient may stay within premium applications. If scale improves and functionality proves reliable, it could move into mainstream categories where protein enrichment and texture control carry clear value.
The EU decision may also influence the wider fermentation ecosystem. Approval gives investors, manufacturers, and co-manufacturers a clearer signal that the regulatory route can be completed. It may encourage further work on fungal biomass, precision fermentation, hybrid formulations, and ingredients developed for specific processing behaviour rather than broad protein replacement claims.
Allergen management, consumer labelling, application testing, shelf-life validation, and cost modelling will shape adoption. Authorisation is not the end point, but it changes the commercial conversation. Fermotein can now move into a European market where protein diversification is shifting from concept to production planning.
